MINNEAPOLIS - OneMedNet Corporation (NASDAQ:ONMD), a curator of Real World Data (RWD) for healthcare systems, has been notified by Nasdaq that it is not in compliance with the stock market's listing requirements due to delayed financial reporting. The company failed to file its Form 10-Q for the quarter ended June 30, 2024, on time, following a previous delay in filing the Form 10-Q for the quarter ended March 31, 2024.
Nasdaq issued a notice on September 10, 2024, granting OneMedNet until October 31, 2024, to submit the overdue documents and regain compliance. If the company does not meet this deadline, it risks having its securities delisted from The Nasdaq Capital Market. Despite this, OneMedNet's securities will continue to be traded under the ticker symbol ONMD.
OneMedNet is working closely with its new auditing firm, WithumSmith+Brown, PC, to complete the necessary filings by the given deadline. However, the company has indicated that while it expects to meet the October 31 deadline, it cannot guarantee this outcome.
The company specializes in managing diverse clinical data types, including electronic health records, lab results, and medical imaging. OneMedNet's iRWD™ platform is utilized by healthcare providers and systems, supporting research in various medical domains such as rare diseases, oncology, and cardiology.
This announcement, required by Nasdaq Listing Rule 5810(b), serves as a public disclosure of the company's current non-compliance status. OneMedNet is committed to enhancing patient outcomes and supporting healthcare innovation through its data management services.
The information in this article is based on a press release statement from OneMedNet Corporation.
In other recent news, OneMedNet Corporation has been making significant strides in its operations. The company has appointed Bob Golden as its new Chief Financial Officer, following the departure of Lisa Embree. Golden brings a wealth of experience in financial management and a strong background in mergers and acquisitions.
In a strategic move, OneMedNet transitioned from The Nasdaq Global Market to The Nasdaq Capital Market, a decision approved by Nasdaq's Listing Qualifications Department. On the leadership front, the company bid farewell to board member Dr. Julianne Huh and welcomed Mr. Andrew B. Zeinfeld to its Board of Directors.
OneMedNet has successfully integrated artificial intelligence into its data curation process, leading to reduced operational costs and increased processing speed. The company also secured private funding of approximately $4.6 million from institutional investors, including affiliates of Off the Chain Capital and Discovery (NASDAQ:WBD) Capital Management.
Furthermore, OneMedNet entered into a Standby Equity Purchase Agreement with investment firm Yorkville Advisors Global, LP. The company also announced a partnership through a Customer Data License Agreement with an undisclosed U.S.-based clinical trial design and software company, and joined the Amazon (NASDAQ:AMZN) Web Services Partner Network (LON:NETW), securing a new client, a computational biotechnology firm. These are the recent developments in OneMedNet's operations.
InvestingPro Insights
In light of OneMedNet Corporation's recent challenges with Nasdaq listing requirements, a closer look at the company's financial health through InvestingPro data provides additional context for investors. OneMedNet, with a market capitalization of $23.47 million, is navigating through a turbulent financial period. The company's revenue in the last twelve months as of Q4 2023 was reported at $1.02 million, which reflects a decline of 11.37% compared to the previous period. However, it's worth noting that quarterly revenue growth showed a positive sign, with an increase of 29.18% in Q4 2023.
The company's financial struggles are further highlighted by its negative gross profit margin of -12.52% and an operating income margin of -819.68%, indicating significant challenges in profitability and operational efficiency. Moreover, OneMedNet's P/E ratio stands at -1.66, pointing towards investor skepticism about the company's earnings potential.
InvestingPro Tips for OneMedNet reveal that the stock has experienced a considerable downturn, falling by 93.15% over the last year. The data also indicates that OneMedNet's short-term obligations exceed its liquid assets, which may raise concerns about the company's ability to meet its immediate financial obligations. Additionally, with a current price far below its 52-week high, the stock is trading at a mere 5.53% of its peak value. It's also important to note that OneMedNet does not pay a dividend, which could influence the investment decisions of income-focused shareholders.
For investors looking for a more in-depth analysis, there are additional InvestingPro Tips available, providing a comprehensive view of OneMedNet's financial position and market performance. These insights can be crucial for making informed investment decisions in the context of the company's recent compliance issues and overall financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.